List of Oravig drug patents
Oravig is owned by Galt Pharms.
Oravig contains Miconazole.
Oravig has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Oravig are:
- US7651698
- US6916485
- US8518442
Oravig was authorised for market use on 16 April, 2010.
Oravig is available in tablet;buccal dosage forms.
Oravig can be used as treatment of oropharyngeal candidiasis.
The generics of Oravig are possible to be released after 11 September, 2022.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7651698 | GALT PHARMS | Prolonged release bioadhesive therapeutic systems |
Sep, 2022
(4 months ago) | |
| US6916485 | GALT PHARMS | Prolonged release bioadhesive therapeutic systems |
Sep, 2022
(4 months ago) | |
| US8518442 | GALT PHARMS | Prolonged release bioadhesive therapeutic systems |
Sep, 2022
(4 months ago) | |
Drugs and Companies using MICONAZOLE ingredient
Market Authorisation Date: 16 April, 2010
Treatment: Treatment of oropharyngeal candidiasis
Dosage: TABLET;BUCCAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic